Skip to main content
. 2020 Dec 8;11(12):1041. doi: 10.1038/s41419-020-03258-3

Fig. 6. UBR2 is widely expressed in cancer cells and contributes to their protection from CICD.

Fig. 6

A UBR2 mRNA expression between healthy tissue (breast) and cancer tissue (invasive breast carcinoma). Data were obtained from the Oncomine database. B Immunoblots of UBR2 expression in the indicated breast cancer cell lines. Actin was used as a loading control. C MDA-MB-231 cells were transfected with the indicated siRNA and treated with Actinomycin D alone (1 μM) as an « apoptosis » stimulus or in combination with the pan-caspase inhibitor qVD-OPH (20 μM) as a « CICD » stimulus for 24 h. Cell death was measured by flow cytometry using a DAPI staining. Data are expressed as mean ± s.d (n = 3). D Real-time quantification of MDA-MB-231 cells transfected with the indicated siRNA and stained for Propidium Iodide in response to treatment with UV (40 J/m2) in combination with qVD-OPH (20 μM) as a CICD stimulus, using the Incucyte ZOOM Live-Cell Imaging system. NT = not treated. E DRUGSURV Database shows that High levels of UBR2 mRNA (n = 91) predicts a poor survival compared to low levels (n = 90) in patients suffering from breast cancer. F graphic summary of our work, see text for details. **p < 0.01, ***p < 0.001 according to a two-way ANOVA. N.S: non-significant. Data are expressed as mean ± s.d (n = 3) immunoblots and incucyte data are representative of 3 individual experiments.